Why are pharmaceutical companies gradually abandoning vaccines?

被引：47

作者：

Offit, PA ^{[1
]}

机构：

[1] Childrens Hosp, Div Infect Dis, Philadelphia, PA USA

[2] Childrens Hosp, Vaccine Educ Ctr, Philadelphia, PA USA

[3] Univ Penn, Sch Med, Philadelphia, PA 19104 USA

来源：

HEALTH AFFAIRS | 2005年 / 24卷 / 03期

关键词：

D O I：

10.1377/hlthaff.24.3.622

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

During the past fifty years, the number of pharmaceutical companies making vaccines has decreased dramatically, and those that still make vaccines have reduced resources to make new ones. Pharmaceutical companies are gradually abandoning vaccines because the research, development, testing, and manufacture of vaccines are expensive and because the market to sell vaccines is much smaller than the market for other drug products. Congressional action could assure both a steady supply of existing vaccines and the promise of vaccines for the future.

引用

页码：622 / 630

页数：9

共 28 条

[21] STUDIES IN HUMAN SUBJECTS ON ACTIVE IMMUNIZATION AGAINST POLIOMYELITIS .1. A PRELIMINARY REPORT OF EXPERIMENTS IN PROGRESS [J].

SALK, JE .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1953, 151 (13) :1081-1098

[22] A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein a to prevent Lyme disease [J].

Sigal, LH ;

Zahradnik, JM ;

Lavin, P ;

Patella, SJ ;

Bryant, G ;

Haselby, R ;

Hilton, E ;

Kunkel, M ;

Adler-Klein, D ;

Doherty, T ;

Evans, J ;

Malawista, SE .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (04) :216-222

[23]

SMITH J, 1990, PATENTING SUN POLIO, P221

[24] Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant [J].

Steere, AC ;

Sikand, VK ;

Meurice, F ;

Parenti, DL ;

Fikrig, E ;

Schoen, RT ;

Nowakowski, J ;

Schmid, CH ;

Laukamp, S ;

Buscarino, C ;

Krause, DS .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (04) :209-215

[25] A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination [J].

Verstraeten, T ;

Jumaan, AO ;

Mullooly, JP ;

Seward, JF ;

Izurieta, HS ;

DeStefano, F ;

Black, SB ;

Chen, RT .

PEDIATRICS, 2003, 112 (02) :E98-E103

[26]

1999, MORBIDITY MORTALITY, V48, P1

[27]

1984, MORBIDITY MORTALITY, V33, P695

[28]

1955, 3 INT POL C PHIL MON, P171

← 1 2 3 →